ABI SCANS & LABS

A unit of Aarthi Scans and Labs

Patient Name : MR. MANIKANDAN K

Age / Gender : 46 years / Male

Patient ID : 124991

Referral : MediWheel

Collection Time : Mar 18, 2023, 08:49 a.m.

Reporting Time : Mar 18, 2023, 12:46 p.m.

Sample ID : 001707723P

Test Description	Value(s)	Unit(s)	Reference Range
COMPLETE BLOOD COUNT (CBC)			
Hemoglobin (Hb)	16.9	gm/dL	13.5 - 18.0
Erythrocyte (RBC) Count	5.74	mil/cu.mm	4.7 - 6.0
Packed Cell Volume (PCV)	48.7	%	42 - 52
Mean Cell Volume (MCV)	84.84	fL	78 - 100
Mean Cell Haemoglobin (MCH)	29.44	pg	27 - 31
Mean Corpuscular Hb Concn. (MCHC)	34.70	g/dL	32 - 36
Red Cell Distribution Width (RDW)	12.0	%	11.5 - 14.0
Total Leucocytes (WBC) Count	8290	cell/cu.mm	4000-10000
Neutrophils	58	%	40 - 80
Lymphocytes	32	%	20 - 40
Monocytes	7	%	2 - 10
Eosinophils	3	%	1 - 6
Basophils	0	%	1-2
Absolute Neutrophil Count	4808.20	/c.mm	2000 - 7000
Absolute Lymphocyte Count	2652.80	/c.mm	1000 - 3000
Absolute Monocyte Count	580.30	/c.mm	200 - 1000
Absolute Eosinophil Count	248.70	/c.mm	20 - 500
Absolute Basophils Count	0	/c.mm	20 - 100
Platelet Count	281	10^3/ul	150 - 450
Mean Platelet Volume (MPV)	10.4	fL	7.2 - 11.7
PCT	0.29	%	0.2 - 0.5
PDW	11.4	%	9.0 - 17.0
ESR	**10.0**	mm/hr	13.5 - 18.0

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Door No. 452/493, PN Road, Millar Stop,
Tirupur - 641 602. Phone: 99434 99994

Obli Towers, #594, D. B. Road - Cowley Brown Road Jn.,
Coimbatore - 641 002. Phone: 99430 99994

email: info@abiscans.com www.abiscans.com

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID : 001707723P

Test Description	Value(s)	Unit(s)	Reference Range
URINE COMPLETE ANALYSIS,			
	Physical Examination		
Quantity	30	ml	-
Colour	Yellow		Pale yellow/Yellow
Appearance	Cloudy		Clear
Specific Gravity	1.020		1.005-1.025
pH	6.0		5.0 - 8.0
Deposit	**Present**		Absent
	Chemical Examination		
Protein	Absent		Absent
Sugar	Absent		Absent
Ketones	Absent		Absent
Bile Salt	Absent		Absent
Bile Pigment	Absent		Absent
Urobilinogen	Normal		Normal
	Microscopic Examination (/hpf)		
Pus Cell	6-8		Upto 5
Epithelial Cells	2-4		Upto 5
Red Blood Cells	Absent		Absent
Casts	Absent		Absent
Crystals	Absent		Absent
Amorphous Deposit	Absent		Absent
Yeast Cells	Absent		Absent
Bacteria	**Present**		Absent
Other findings	Not seen		Not seen

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
STOOL ROUTINE ANALYSIS			
Color	Yellowish		Brown
Consistency	Semisolid		Solid - Semi solid
Reaction (pH)	Alkaline		Acidic - Alkaline
Method : Methyl Red & Bromothymol Blue			
Mucous	Absent		Absent
Blood	Absent		Absent
Pus cells	2-3/hpf	/hpf	Few
Epithelial cells	1-2/hpf	/hpf	--
RBC	Absent	/hpf	Absent
Ova	Not found	/hpf	Absent
Cyst	Not found	/hpf	Absent
Starch granules	Absent	/hpf	None to small amount
Vegetable cells	Absent	/hpf	--
Fat globules	Absent	/hpf	Absent
Others	Nil	/hpf	
Method : Microscopy (Concentration technique)			

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

ABI SCANS & LABS

A unit of Aarthi Scans and Labs

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
BLOOD GROUP & RH TYPING			
Blood Group (ABO typing) Method : Manual-Hemagglutination	"O"		
RhD Factor (Rh Typing) Method : Manual hemagglutination	Positive		

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Door No. 452/493, PN Road, Millar Stop,
Tirupur - 641 602. Phone: 99434 99994

Obli Towers, #594, D. B. Road - Cowley Brown Road Jn.,
Coimbatore - 641 002. Phone: 99430 99994

email: info@abiscans.com www.abiscans.com

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
urine glucose			
urine glucose (R)			
NEGATIVE			

DR.K.MURALEKAARTHIC
MD(Patho)

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :


001707723P

Test Description	Value(s)	Unit(s)	Reference Range
Glycosylated HbA1c			
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD	10.2	%	
Method : (HPLC, NGSP certified)			
Estimated Average Glucose :	246.04	mg/dL	-

Interpretation

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
THYROID PROFILE TEST - TOTAL			
T3-Total	110.0	ng/dL	60 - 200
T4-Total	5.8	ug/dL	4.52 - 12.8
TSH-Ultrasensitive	2.51	uIU/mL	0.32 - 5.5
Method : CLIA			

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
LIPID PROFILE			
Cholesterol-Total Method : Spectrophotometry	192.0	mg/dL	Desirable level | < 200 Borderline High | 200-239 High | >or = 240
Triglycerides Method : Serum, Enzymatic, endpoint	84.0	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
HDL Cholesterol Method : Serum, Direct measure-PEG	**36.0**	mg/dL	Normal: > 40 Major Risk for Heart: < 40
LDL Cholesterol Method : Enzymatic selective protection	139.20	mg/dL	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190
VLDL Cholesterol Method : Serum, Enzymatic	16.80	mg/dL	6 - 38
CHOL/HDL Ratio Method : Serum, Enzymatic	**5.33**		3.5 - 5.0
LDL/HDL Ratio Method : Serum, Enzymatic	**3.87**		2.5 - 3.5

Note:
8-10 hours fasting sample is required.

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID : 001707723P

Test Description	Value(s)	Unit(s)	Reference Range
RENAL PROFILE			
Urea	**11.0**	mg/dL	19-42
Method : Uricase			
Blood Urea Nitrogen-BUN	**5.13**	mg/dL	9-20
Method : Serum, Urease			
Creatinine	**0.62**	mg/dL	0.66-1.25
Method : Serum, Jaffe			
Uric Acid	4.1	mg/dL	3.5-8.5
Method : Serum, Uricase			

Remark:

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID : 001707723P

Test Description	Value(s)	Unit(s)	Reference Range
LIVER FUNCTION TEST			
Total Protein	6.8	g/dL	6.3-8.2
Method : Serum, Biuret, reagent blank end point			
Albumin	3.9	g/dL	3.5-5.0
Method : Serum, Bromocresol green			
Globulin	2.90	g/dL	1.8 - 3.6
Method : Serum, EIA			
A/G Ratio	1.34		1.2 - 2.2
Method : Serum, EIA			
Bilirubin - Total	0.5	mg/dL	0.3-1.2
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.2	mg/dL	< 0.2
Method : Serum, Diazotization			
Bilirubin - Indirect	0.30	mg/dL	0.1 - 1.0
Method : Serum, Calculated			
SGOT	38.0	U/L	17-59
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	27.0	U/L	21-72
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	101.0	U/L	30 - 120
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae	33.0	U/L	< 55
Method : Serum, G-glutamyl-carboxy-nitoanilide			

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID : 001707723P

Test Description	Value(s)	Unit(s)	Reference Range
PSA-Total (Prostate-specific antigen-Total)			
PSA Profile *			
PSA (Prostate Specific Antigen)-Total	< 0.01	ng/mL	0 - 4.0

Method : Serum, CLIA

Interpretation:

1. Increased levels are noted in Prostate cancer, Bengin prostatic hypertrophy, Prostatitis

PSA (Prostate-Specificantigen)-Free *	-	ng/mL	0.0 - 0.5

Method : Serum, CLIA

Interpretation & Remarks:

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably.
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease
- Specimens drawn from patients undergoing prostate manipulation, especially needle biopsy and transurethral resection, may show erroneously high prostatic-specific antigen (PSA) results. Care should be taken that specimens are drawn before these procedures are performed.
- The percentage of free PSA can be used to estimate how likely it is that a biopsy will show cancer.
- If the percentage of free PSA is higher than 25%, the likelihood of prostate cancer is about 8%.
- If the percentage of free PSA is less than 10%, then the likelihood of prostate cancer rises to 56%.

Free PSA / Total PSA %	-		-

Method : Serum

Interpretation

- When total prostate-specific antigen (PSA) concentration is <2.0 ng/mL, the probability of prostate cancer in asymptomatic men is low, further testing and free PSA may provide little additional information. When total PSA concentration is >10.0 ng/mL, the probability of cancer is high and prostate biopsy is generally recommended.
- The total PSA range of 4.0 to 10.0 ng/mL has been described as a diagnostic "gray zone," in which the free:total PSA ratio helps to determine the relative risk of prostate cancer (see table below). Therefore, some urologists recommend using the free:total ratio to help select which men should undergo biopsy. However even a negative result of prostate biopsy does not

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range

rule-out prostate cancer. Up to 20% of men with negative biopsy results have subsequently been found to have cancer.

Based on free:total PSA ratio: the percent probability of finding prostate cancer on a needle biopsy by age in years:

Free:total PSA ratio	50-59 years	60-69 years	> or =70 years
< or =0.10	49.2%	57.5%	64.5%
0.11-0.18	26.9%	33.9%	40.8%
0.19-0.25	18.3%	23.9%	29.7%
>0.25	9.1%	12.2%	15.8%

Cautions

- Normal results do not eliminate the possibility of prostate cancer.
- Values obtained with different assay methods or kits may be different and cannot be used interchangeably
- Tumor markers are not specific for malignancy. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Interfering factors :

- Prostatic massage
- Proctoscopy
- Prostatic biopsy
- Prostate cancer patients receiving treatment with antiandrogens and luteinizing hormone-releasing factor agonists may exhibit markedly decreased levels of PSA. Also, men treated for benign prostatic hyperplasia with inhibitors of 5-alpha-reductase (finasteride) may demonstrate a significant reduction in PSA levels compared to values before treatment. Care should be taken in interpreting values for these individuals.
- In patients receiving therapy with high biotin doses (ie, >5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration.

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
GLUCOSE (F)			
Glucose fasting Method : GOD-POD	**195.0**	mg/dL	Normal: 70 - 120

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate

Patient Name : MR. MANIKANDAN K
Age / Gender : 46 years / Male
Patient ID : 124991

Referral : MediWheel
Collection Time : Mar 18, 2023, 08:49 a.m.
Reporting Time : Mar 18, 2023, 12:46 p.m.
Sample ID :

001707723P

Test Description	Value(s)	Unit(s)	Reference Range
GLUCOSE (PP)			
Blood Glucose-Post Prandial	**374.0**	mg/dL	80 - 140
Method : GOD-POD			

Medical Remark :

Rechecked*

DR.K.MURALEKAARTHIC
MD(Patho)

Scan to Validate